Area of research
Psychiatry and Mental health · Physiology
Research interest
Dr. Saykin trained in clinical neuropsychology at Hahnemann Medical College (now Drexel University) followed by post-doctoral experience at the University of Pennsylvania. In 2006, after serving on the faculty at Penn and then Dartmouth, he joined Indiana University as director of the IU Center for Neuroimaging. In 2013, he was appointed as director of the NIA-designated Indiana Alzheimer’s Disease Research Center. In 2014, co-founded the IU Network Science Institute (IUNI) where he continues to serve on the Scientific Council. His multidisciplinary expertise is in the areas of cognitive neuroscience, multimodal neuroimaging and human genetics. Dr. Saykin’s research has been funded by the NIA, NINDS, NCI, NIBIB, and NSF, as well as major foundations.
Predicting the progression of MCI and Alzheimer's disease on structural brain integrity and other features with machine learning.
Associations of circulating c-reactive protein levels with central Alzheimer’s disease biomarkers
Heterogeneous patterns of cognitive decline in Alzheimer's disease across three domains of cognition.
Interaction of endocrine therapy for breast cancer with APOE4 status on cognition over 5-year follow-up.
Neighborhood deprivation on increasing deficit accumulation in older breast cancer survivors and noncancer control individuals.
GWAS meta-analysis of cerebrospinal fluid Alzheimer’s biomarkers reveals loci regulating lipids, brain volume and autophagy
Learning a Continuous Progression Trajectory of Amyloid in Alzheimer disease
Epigenetic signatures linking environmental exposure, cortical structure and psychiatric traits
Longitudinal Brain Atrophy Patterns in Dementia and Cognitive Decline: the Framingham Heart Study
Gene-Modulated Network Diffusion for Improved Modeling of Amyloid-
<i>β</i>
Spread in Alzheimer’s Disease
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging
Human lifespan changes in the brain's functional connectome.
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex
White Matter Abnormalities and Cognition in Aging and Alzheimer Disease
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials.
Transferability of European-derived Alzheimer’s disease polygenic risk scores across multiancestry populations
Individual bioenergetic capacity as a potential source of resilience to Alzheimer’s disease
Sex and APOE ε4 allele differences in longitudinal white matter microstructure in multiple cohorts of aging and Alzheimer's disease.
Individual bioenergetic capacity as a potential source of resilience to Alzheimer's disease.
Temporal Dynamics and Biological Variability of Alzheimer Biomarkers
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment.
Dynamic diffusion-weighted imaging of intracranial cardiac impulse propagation along arteries to arterioles in the aging brain.
Depressive symptom trajectories in older breast cancer survivors: the Thinking and Living with Cancer Study.
Amyloid PET predicts longitudinal functional and cognitive trajectories in a heterogeneous cohort.
WMH Contributions to Cognitive Impairment: Rationale and Design of the Diverse VCID Study.
Amyloid PET predicts longitudinal functional and cognitive trajectories in a heterogeneous cohort
Cell-specific transcriptional signatures of vascular cells in Alzheimer's disease: perspectives, pathways, and therapeutic directions.
The effect of Alzheimer's disease genetic factors on limbic white matter microstructure.